[Special Stock] Komipharm Hits Upper Limit on COVID-19 Emergency Clinical Trial Plan

[Asia Economy Reporter Geum Bo-ryeong] Komipharm recorded a limit-up from the morning of the 27th as news spread that it had applied for an emergency clinical trial plan targeting patients infected with the novel coronavirus disease (COVID-19).

As of 9:50 a.m. that day, Komipharm showed a price of 17,550 won, up 30% (4,050 won) compared to the previous day.

Komipharm announced the day before that it had applied to the domestic Ministry of Food and Drug Safety for an emergency clinical trial plan for Panaphix, a new drug substance under development.

Komipharm explained, "This clinical plan aims to fundamentally and rapidly treat pneumonia caused by viral infection by inhibiting the activation of immune cell signaling factors, thereby suppressing the release of inflammation-inducing cytokines such as TNF-α, IL-1β, and IL-6."

The clinical trial is named "Phase 2/3 clinical trial of PAX-1 therapy orally administered to patients with COVID-19 infected pneumonia (NCIP)," and the clinical trial subjects are 100 patients diagnosed with COVID-19.

This content was produced with the assistance of AI translation services.